Evidence map›Paper›PMID 42374028›Full record

ArticleBlood cancer journal2026

Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma.

Bon Park, Kyung Ju Ryu, Min Kyu Choi, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bon ParkDepartment of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
Kyung Ju RyuDepartment of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
Min Kyu ChoiSeoul National University College of Medicine, Seoul, Korea.
Sang Eun YoonDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0002-0379-5297
Won Seog KimDepartment of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.
Seok Jin KimDepartment of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea. kstwoh@skku.edu.ORCID http://orcid.org/0000-0002-2776-4401

Funding

Korea Health Industry Development Institute (KHIDI) RS-2020-KH088685National Research Foundation of Korea (NRF) RS-2024-00345897
6 · The paper itself

Abstract

Rituximab, an anti-CD20 monoclonal antibody, is a cornerstone of therapy for diffuse large B-cell lymphoma (DLBCL), yet a substantial proportion of patients develop treatment failure. While loss of CD20 expression has been considered a major mechanism of resistance, additional mechanisms limiting effective antibody binding remain incompletely understood. We hypothesized that circulating CD20-positive large extracellular vesicles (EV

Indexed as

Antigens, CD20Antineoplastic Agents, ImmunologicalExtracellular VesiclesLymphoma, Large B-Cell, DiffuseRituximabAgedAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCyclophosphamideFemaleHumansMaleMiddle AgedPrednisonePrognosisTreatment OutcomeAntigens, CD20Antineoplastic Agents, ImmunologicalCyclophosphamidePrednisoneRituximab

Identifiers

PMID42374028
PMCPMC13575117

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.